Zum Inhalt springen

Nur-Lesen-Fassung: Das Forschungsinformationssystem (FIS) ist aus Sicherheitsgründen vorübergehend durch diese Nur-Lesen-Fassung ersetzt. Alle öffentlichen Inhalte und Volltexte sind weiterhin abrufbar; Anmeldung, Bearbeitung, Einreichung und Statistiken stehen nicht zur Verfügung. Bei Fragen: fis@uni-bamberg.de

Start › Publikationen › Improvements in Glycemic Control With a Digital Diabetes Logbook : Secondary Analysis of a Randomized Controlled Trial Enriched by Observational, Real-World Data

Publikation

Improvements in Glycemic Control With a Digital Diabetes Logbook : Secondary Analysis of a Randomized Controlled Trial Enriched by Observational, Real-World Data

Ehrmann, Dominic; Ruch, Bernhard; Mitter, Michael; u. a. (2025): Improvements in Glycemic Control With a Digital Diabetes Logbook : Secondary Analysis of a Randomized Controlled Trial Enriched by Observational, Real-World Data, in: Journal of Medical Internet Research, Richmond, Va.: JMIR Publications, Jg. 27, Nr. e68933, S. 1–14, doi: 10.2196/68933.

Details

Fakultät/Lehrstuhl
Autorin(nen)/Autor(en)
Ruch, Bernhard
Mitter, Michael
Kober, Johanna
Schäfer, Vanessa
Silbermann, Stephan
Titel der Zeitschrift
Journal of Medical Internet Research
ISSN
1438-8871
Verlagsangabe
JMIR Publications : Richmond, Va.
Erscheinungsjahr
2025
Jahrgang
27
Heft
e68933
Sprache(n)
Englisch
DOI
Abstract

Background: The treatment of diabetes requires substantial self-management. Digital tools can help reduce the burden of self-management and may improve glycemic control.

Objective: This study aims to determine whether the use of a digital diabetes logbook increased the likelihood of achieving optimal glycemic control (glycated hemoglobin [HbA1c] ≤6.5%) after 3 months, based on a secondary analysis of randomized controlled trial (RCT) data. A secondary objective was to evaluate the long-term impact of the logbook on mean blood glucose levels over 3 and 12 months using observational, real-world data (RWD).

Methods: Data from 342 participants with type 1 or type 2 diabetes enrolled in the mySugr PRO-RCT were analyzed. A robust logistic regression was performed to examine the likelihood of achieving optimal glycemic control, defined as an HbA1c value ≤6.5% at the 3-month follow-up. The dependent variable was the dichotomous outcome indicating whether this threshold was met. The primary independent variable was group allocation, with baseline HbA1c included as a covariate. For the analysis of RWD, a total of 2861 participants with type 1 or type 2 diabetes were identified using propensity score matching to align their characteristics with those of the RCT participants closely. One-sample t tests were conducted to analyze changes in mean blood glucose separately for each diabetes type, from baseline to 3 months of app use, and from baseline to 12 months of app use (in a subcohort of 1176 participants).

Results: The RCT data showed that the likelihood of achieving optimal glycemic control was nearly doubled in the intervention group compared with the control group (odds ratio 2.24, 95% CI 1.12-4.47; P=.02). RWD indicated that mean blood glucose levels significantly improved over 3 months of app use in both groups (type 1: –16.3 mg/dL; 95% CI –20.6 to –12.4; P<.001 and type 2: –27.3 mg/dL, 95% CI –28.7 to –25.9; P<.001). Participants with an estimated HbA1c>8.5% at baseline (before app use) showed the greatest reductions in mean blood glucose (type 1: –82.2 mg/dL; 95% CI –102.0 to –61.8; P<.001; type 2: –104.6 mg/dL, 95% CI –109.1 to –100.3; P<.001). Long-term analyses revealed a sustained reduction in mean blood glucose over a 12-month period, with a mean decrease of –19.8 mg/dL (95% CI –21.8 to –17.9; P<.001) after 12 months of app use in the total RWD sample.

Conclusions: The secondary analysis of the RCT demonstrated a significant increase in the likelihood of achieving optimal glycemic control after 3 months of using the mySugr logbook. This finding was supported by observational, real-world data, which showed significant reductions in mean blood glucose after 3 and 12 months of app use—particularly among individuals with elevated baseline HbA1c levels.

Trial Registration: German Clinical Trials Register DRKS00022923; https://drks.de/search/en/trial/DRKS00022923/details

Freie Schlagwort(e)
randomized controlled trial
real-world data
glycemic control
digital health app
type 1 diabetes
type 2 diabetes
DDC-Klassifikation
150 Psychologie
RVK-Klassifikation
CM 4200
Dokumenttyp
Artikel in einer Zeitschrift / Postprint
URI
Datum der Freischaltung
11.08.2026

Permalink: https://fis.uni-bamberg.de/handle/uniba/116737 · Daten als JSON · Zitieren: BibTeX · RIS

Datenstand: 15.11.2026

Eingeschränkter Lesezugriff: Anmeldung, Bearbeitung und Einreichung sind vorübergehend deaktiviert.